

# Paul G Richardson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5949616/paul-g-richardson-publications-by-citations.pdf>

**Version:** 2023-12-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

856  
papers

71,548  
citations

136  
h-index

253  
g-index

889  
ext. papers

81,184  
ext. citations

5.7  
avg, IF

7.36  
L-index

#	Paper	IF	Citations
856	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e538-48	21.7	2253
855	A phase 2 study of bortezomib in relapsed, refractory myeloma. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2609-17	59.2	2196
854	Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2487-98	59.2	2097
853	BET bromodomain inhibition as a therapeutic strategy to target c-Myc. <i>Cell</i> , <b>2011</b> , 146, 904-17	56.2	2045
852	Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 906-17	59.2	1580
851	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e328-e346	21.7	1155
850	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2863-9	2.2	976
849	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 621-31	59.2	935
848	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1319-1331	59.2	930
847	Lenalidomide after stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1770-81	59.2	862
846	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> , <b>2001</b> , 98, 210-6	2.2	773
845	Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. <i>Blood</i> , <b>2000</b> , 96, 2943-2950	2.2	772
844	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1207-19	59.2	761
843	NF-kappa B as a therapeutic target in multiple myeloma. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 16639-47	39.4	723
842	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. <i>Nature Reviews Cancer</i> , <b>2007</b> , 7, 585-98	31.3	699
841	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood</i> , <b>2002</b> , 100, 3063-7	2.2	693
840	Oral ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1621-34	59.2	684

839	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , <b>2011</b> , 117, 4691-5	2.2	681
838	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , <b>2010</b> , 116, 679-86	2.2	680
837	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. <i>Cancer Cell</i> , <b>2014</b> , 25, 91-101	24.3	657
836	The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. <i>Blood</i> , <b>2003</b> , 101, 2377-80	2.2	631
835	Molecular sequelae of proteasome inhibition in human multiple myeloma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 14374-9	11.5	630
834	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. <i>Cancer Cell</i> , <b>2005</b> , 8, 407-19	24.3	611
833	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1311-1320	59.2	608
832	Multiple myeloma. <i>Lancet, The</i> , <b>2009</b> , 374, 324-39	40	605
831	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1195-206	21.7	604
830	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1551-1560	40	581
829	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , <b>2012</b> , 26, 149-57	10.7	580
828	Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. <i>Blood</i> , <b>2002</b> , 99, 4525-30	2.2	576
827	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , <b>2014</b> , 5, 2997	17.4	564
826	Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3113-20	2.2	529
825	Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 8567-72	11.5	526
824	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. <i>Blood</i> , <b>2003</b> , 101, 1530-4	2.2	488
823	Proteasome inhibition as a novel therapeutic target in human cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 630-9	2.2	471
822	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. <i>Blood</i> , <b>2006</b> , 108, 3458-64	2.2	446

821	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , <b>2007</b> , 110, 3557-60	2.2	443
820	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , <b>2015</b> , 125, 2068-74	2.2	426
819	Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. <i>Oncogene</i> , <b>2002</b> , 21, 5673-83	9.2	423
818	Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 157-68	4.7	406
817	A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. <i>Cancer Cell</i> , <b>2012</b> , 22, 345-58	24.3	393
816	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , <b>2012</b> , 120, 947-59	2.2	370
815	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. <i>Blood</i> , <b>2008</b> , 112, 1329-37	2.2	366
814	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3279-3289	2.2	361
813	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. <i>Blood</i> , <b>2006</b> , 107, 4053-62	2.2	360
812	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. <i>Blood</i> , <b>2001</b> , 98, 428-35	2.2	358
811	Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2259-66	2.2	352
810	Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. <i>Blood</i> , <b>2002</b> , 99, 4079-86	2.2	341
809	The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. <i>Oncogene</i> , <b>2001</b> , 20, 4519-27	9.2	336
808	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i> , <b>2012</b> , 119, 4375-82	2.2	335
807	TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. <i>Blood</i> , <b>2001</b> , 98, 795-804	2.2	335
806	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. <i>Blood</i> , <b>2007</b> , 109, 3177-88	2.2	314
805	Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. <i>Cancer Research</i> , <b>2002</b> , 62, 4996-5000	10.1	300
804	Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. <i>Blood</i> , <b>2002</b> , 100, 4337-43	2.2	297

803	Blockade of XBP1 splicing by inhibition of IRE1 $\beta$ s a promising therapeutic option in multiple myeloma. <i>Blood</i> , <b>2012</b> , 119, 5772-81	2.2	296
802	Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4976-84	2.2	290
801	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Annual Review of Medicine</i> , <b>2006</b> , 57, 33-47	17.4	289
800	Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. <i>Blood</i> , <b>2009</b> , 114, 1046-52	2.2	285
799	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 207-221	21.7	281
798	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. <i>Blood</i> , <b>2005</b> , 106, 3777-84	2.2	278
797	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e206-e217	21.7	275
796	Molecular sequelae of histone deacetylase inhibition in human malignant B cells. <i>Blood</i> , <b>2003</b> , 101, 4055-62	2.2	274
795	Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> , <b>2014</b> , 123, 3128-38	2.2	273
794	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , <b>2016</b> , 128, 37-44	2.2	272
793	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , <b>2014</b> , 123, 1826-32	2.2	271
792	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i> , <b>2003</b> , 102, 1578-82	2.2	270
791	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. <i>Blood</i> , <b>2013</b> , 121, 2975-87	2.2	268
790	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1811-1822	59.2	268
789	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 727-738	59.2	266
788	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. <i>British Journal of Haematology</i> , <b>2005</b> , 128, 192-203	4.5	265
787	In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5311-21	12.9	256
786	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 587-600	2.2	255

785	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. <i>Blood</i> , <b>2013</b> , 122, 2331-7	2.2	255
784	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , <b>2019</b> , 394, 2096-2107	4.0	253
783	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 895-903	4.5	252
782	Antimyeloma activity of heat shock protein-90 inhibition. <i>Blood</i> , <b>2006</b> , 107, 1092-100	2.2	249
781	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. <i>Nature Medicine</i> , <b>2010</b> , 16, 483-9	50.5	247
780	Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. <i>Cancer Control</i> , <b>2003</b> , 10, 361-9	2.2	237
779	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , <b>2011</b> , 117, 6063-73	2.2	234
778	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. <i>Blood</i> , <b>2004</b> , 103, 1787-90	2.2	230
777	Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4784-90	2.2	227
776	A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. <i>Blood</i> , <b>2010</b> , 115, 5202-13	2.2	221
775	A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. <i>Blood</i> , <b>2014</b> , 123, 706-16	2.2	215
774	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. <i>Blood</i> , <b>2007</b> , 109, 2604-6	2.2	215
773	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4607-18	12.9	214
772	Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3518-25	2.2	213
771	Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 2034-42	6.1	213
770	Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 448-55	2.2	211
769	CD38 antibodies in multiple myeloma: back to the future. <i>Blood</i> , <b>2018</b> , 131, 13-29	2.2	209
768	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1503-1512	21.7	207

767	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. <i>Blood</i> , <b>2003</b> , 102, 2615-22	2.2	207
766	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , <b>2014</b> , 15, 333-42	21.7	206
765	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1544-57	2.2	204
764	Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. <i>Cancer</i> , <b>2005</b> , 103, 1195-200	6.4	199
763	Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. <i>Cancer Cell</i> , <b>2009</b> , 16, 309-23	24.3	197
762	Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 1005-17	4.7	196
761	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , <b>2018</b> , 132, 2456-2464	2.2	191
760	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , <b>2020</b> , 136, 936-945	2.2	189
759	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. <i>Nature Medicine</i> , <b>2014</b> , 20, 599-606	50.5	189
758	Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , <b>2006</b> , 66, 6675-82	10.1	187
757	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , <b>2016</b> , 127, 1656-65	2.2	184
756	Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. <i>Drugs</i> , <b>1998</b> , 56, 307-35	12.1	181
755	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4028-37	12.9	178
754	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 502-7	1.9	174
753	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , <b>2008</b> , 111, 1654-64	2.2	174
752	Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2911-2918	2.2	172
751	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. <i>Blood</i> , <b>2010</b> , 116, 3227-37	2.2	172
750	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. <i>Blood</i> , <b>2014</b> , 124, 1038-46	2.2	171

749	The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 1564-73	7.5	171
748	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. <i>Blood</i> , <b>2010</b> , 116, 4906-15	2.2	170
747	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. <i>Blood</i> , <b>2011</b> , 117, 393-402	2.2	169
746	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. <i>British Journal of Haematology</i> , <b>2005</b> , 131, 71-3	4.5	169
745	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. <i>Blood</i> , <b>2016</b> , 127, 3225-36	2.2	168
744	High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. <i>Biology of Blood and Marrow Transplantation</i> , <b>2007</b> , 13, 183-96	4.7	168
743	Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1960-5	2.2	167
742	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , <b>2004</b> , 104, 4188-93	2.2	167
741	Latest advances and current challenges in the treatment of multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 135-43	19.4	165
740	Resolving the daratumumab interference with blood compatibility testing. <i>Transfusion</i> , <b>2015</b> , 55, 1545-54.9	5.9	158
739	PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. <i>Blood</i> , <b>2010</b> , 116, 1460-8	2.2	157
738	Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. <i>Oncogene</i> , <b>2002</b> , 21, 1346-58	9.2	157
737	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. <i>Blood</i> , <b>2005</b> , 106, 1794-800	2.2	157
736	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , <b>2016</b> , 127, 681-95	2.2	154
735	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , <b>2014</b> , 123, 1461-9	2.2	152
734	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. <i>Oncogene</i> , <b>2003</b> , 22, 8386-93	9.2	151
733	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 781-794	21.7	150
732	Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4767-73	12.9	150



731	The proteasome and proteasome inhibitors in multiple myeloma. <i>Cancer and Metastasis Reviews</i> , <b>2017</b> , 36, 561-584	9.6	150
730	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , <b>2012</b> , 119, 3003-15	2.2	150
729	Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. <i>Cancer Research</i> , <b>2005</b> , 65, 11712-20	10.1	149
728	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3307-3315	12.9	148
727	Current treatment landscape for relapsed and/or refractory multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 42-54	19.4	146
726	Proteasome inhibitor therapy in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 686-92	6.1	142
725	Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5713-9	2.2	141
724	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1641-1653	21.7	141
723	Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3196-203	2.2	139
722	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , <b>2008</b> , 112, 4425-31	2.2	139
721	New drugs for myeloma. <i>Oncologist</i> , <b>2007</b> , 12, 664-89	5.7	138
720	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 607-12	5.5	136
719	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1569-1578	21.7	133
718	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. <i>Blood</i> , <b>2013</b> , 121, 1961-7	2.2	132
717	VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6086-93	2.2	131
716	Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. <i>Cancer Research</i> , <b>2005</b> , 65, 5898-906	10.1	131
715	Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , <b>2009</b> , 114, 772-8	2.2	130
714	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. <i>Lancet Haematology,the</i> , <b>2015</b> , 2, e516-27	14.6	129

713	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. <i>Blood</i> , <b>2011</b> , 117, 4409-19	2.2	125
712	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 607-612	5.5	122
711	A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. <i>Blood</i> , <b>2012</b> , 119, 2764-7	2.2	119
710	Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1422-8	2.2	118
709	MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5887-94	12.9	118
708	Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3696-703	2.2	117
707	Thalidomide: emerging role in cancer medicine. <i>Annual Review of Medicine</i> , <b>2002</b> , 53, 629-57	17.4	117
706	How I treat multiple myeloma in younger patients. <i>Blood</i> , <b>2009</b> , 114, 5436-43	2.2	116
705	Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. <i>Cancer</i> , <b>2006</b> , 106, 1316-9	6.4	116
704	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 2039-2051	4.7	114
703	Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 2387-95	12.9	114
702	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. <i>Oncogene</i> , <b>2004</b> , 23, 8766-76	9.2	112
701	Cytokines modulate telomerase activity in a human multiple myeloma cell line. <i>Cancer Research</i> , <b>2002</b> , 62, 3876-82	10.1	112
700	Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. <i>Haematologica</i> , <b>2006</b> , 91, 929-34	6.6	112
699	Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. <i>Cancer Research</i> , <b>2004</b> , 64, 2846-52	10.1	110
698	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 537-49	4.5	107
697	Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4243-9	2.2	107
696	Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 2558-60	27.4	107

695	The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , <b>2002</b> , 62, 5019-26	10.1	107
694	Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. <i>Mayo Clinic Proceedings</i> , <b>2004</b> , 79, 875-82	6.4	106
693	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. <i>Blood</i> , <b>2004</b> , 103, 3158-66	2.2	106
692	Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 367-79	4.5	104
691	Treatment options for relapsed and refractory multiple myeloma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1264-77	12.9	103
690	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , <b>2007</b> , 137, 429-35	4.5	103
689	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. <i>Blood</i> , <b>2007</b> , 110, 1656-63	6.3	103
688	Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. <i>Current Opinion in Hematology</i> , <b>2003</b> , 10, 451-62	3.3	102
687	2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. <i>Blood</i> , <b>2002</b> , 100, 2187-94	2.2	102
686	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 896-905	4.5	101
685	The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. <i>Hematology/Oncology Clinics of North America</i> , <b>2007</b> , 21, 1007-34, vii-viii	3.1	101
684	Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. <i>Blood</i> , <b>2003</b> , 101, 703-5	2.2	101
683	Multiple myeloma. <i>Annual Review of Medicine</i> , <b>2011</b> , 62, 249-64	17.4	99
682	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. <i>European Journal of Haematology</i> , <b>2011</b> , 86, 23-31	3.8	99
681	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , <b>2016</b> , 127, 713-21	2.2	99
680	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , <b>2016</b> , 3, e506-e515	14.6	98
679	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 109	7	97
678	Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , <b>2010</b> , 115, 834-45	2.2	94

677	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 783-91	4.5	94
676	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology, the</i> , <b>2017</b> , 4, e431-e442	14.6	93
675	How I treat plasma cell leukemia. <i>Blood</i> , <b>2012</b> , 120, 2376-89	2.2	93
674	Kidney disease and multiple myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2013</b> , 8, 2007-17	6.9	93
673	Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 7540-6	12.9	93
672	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1563-1573	40	92
671	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , <b>2010</b> , 116, 3743-50	2.2	91
670	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. <i>British Journal of Haematology</i> , <b>2008</b> , 143, 46-53	4.5	91
669	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. <i>Cancer</i> , <b>2005</b> , 104, 2141-8	6.4	91
668	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 13162-13167	11.5	89
667	The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , <b>2002</b> , 1, 539-44	6.1	88
666	Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. <i>Molecular Cancer Therapeutics</i> , <b>2002</b> , 1, 851-60	6.1	88
665	FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. <i>Cancer Research</i> , <b>2005</b> , 65, 7478-84	10.1	86
664	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 729-40	4.5	84
663	Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. <i>Cancer Research</i> , <b>2004</b> , 64, 7500-6	10.1	84
662	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , <b>2016</b> , 128, 1821-1828	2.2	82
661	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. <i>Cancer</i> , <b>2018</b> , 124, 4032-4043	6.4	82
660	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. <i>Blood</i> , <b>2014</b> , 123, 632-9	2.2	81

659	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , <b>2008</b> , 143, 222-9	4.5	81
658	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , <b>2015</b> , 126, 391-391	2.2	80
657	Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. <i>Cancer Research</i> , <b>2008</b> , 68, 5216-25	10.1	79
656	GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Blood</i> , <b>2004</b> , 103, 3474-9	2.2	79
655	Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. <i>Journal of Cellular Biochemistry</i> , <b>2007</b> , 101, 950-68	4.7	77
654	Proteasome Inhibition in the Treatment of Cancer. <i>Cell Cycle</i> , <b>2005</b> , 4, 289-295	4.7	77
653	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1317-1330	21.7	76
652	Clinical update: proteasome inhibitors in hematologic malignancies. <i>Cancer Treatment Reviews</i> , <b>2003</b> , 29 Suppl 1, 33-9	14.4	75
651	New proteasome inhibitors in myeloma. <i>Current Hematologic Malignancy Reports</i> , <b>2012</b> , 7, 258-66	4.4	74
650	Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2008</b> , 143, 537-40	4.5	74
649	Bortezomib in the front-line treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 1053-72	3.5	73
648	TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 400-5	7.1	73
647	Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. <i>Lancet Oncology</i> , <b>2011</b> , 12, 263-72	21.7	72
646	The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. <i>British Journal of Haematology</i> , <b>1999</b> , 107, 485-93	4.5	72
645	Promising therapies in multiple myeloma. <i>Blood</i> , <b>2015</b> , 126, 300-10	2.2	71
644	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2009</b> , 146, 164-70	4.5	71
643	Multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , <b>2004</b> , 2004, 237-56	3.1	71
642	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 222-230	4.5	70

641	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. <i>Blood</i> , <b>2011</b> , 118, 535-43	2.2	70
640	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. <i>Blood</i> , <b>2004</b> , 104, 2458-66	2.2	70
639	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , <b>2017</b> , 130, 2610-2618	2.2	69
638	Prediction of veno-occlusive disease using biomarkers of endothelial injury. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 1180-5	4.7	69
637	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , <b>2016</b> , 127, 1138-50	2.2	68
636	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. <i>Cancer Discovery</i> , <b>2015</b> , 5, 972-87	24.4	67
635	Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 623-33	5.5	66
634	Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1916-23	2.2	66
633	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>Blood</i> , <b>2019</b> , 134, 123-133	2.2	65
632	Intracellular NAD <sup>+</sup> depletion enhances bortezomib-induced anti-myeloma activity. <i>Blood</i> , <b>2013</b> , 122, 1243-55	2.2	65
631	Identification and validation of novel therapeutic targets for multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6345-50	2.2	65
630	In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3019-31	12.9	64
629	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. <i>British Journal of Haematology</i> , <b>2004</b> , 125, 343-52	4.5	64
628	Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. <i>British Journal of Haematology</i> , <b>2006</b> , 132, 385-97	4.5	64
627	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. <i>Haematologica</i> , <b>2011</b> , 96, 1170-9	6.6	63
626	Dual inhibition of canonical and noncanonical NF- $\kappa$ B pathways demonstrates significant antitumor activities in multiple myeloma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4669-81	12.9	63
625	Biologic sequelae of $\kappa$ B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. <i>Blood</i> , <b>2009</b> , 113, 5228-36	2.2	62
624	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , <b>2016</b> , 7, 10258	17.4	61

623	Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. <i>Blood</i> , <b>2012</b> , 120, 3958-67	2.2	61
622	Monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , <b>2011</b> , 154, 745-54	4.5	61
621	Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. <i>Seminars in Hematology</i> , <b>2005</b> , 42, S9-15	4	61
620	Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7153-60	12.9	60
619	Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 816-827	4.5	59
618	Current strategies for treatment of relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , <b>2014</b> , 7, 97-111	2.8	58
617	Sequence analysis of $\beta$ subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. <i>Blood</i> , <b>2012</b> , 120, 4513-6	2.2	58
616	Drug safety evaluation of defibrotide. <i>Expert Opinion on Drug Safety</i> , <b>2013</b> , 12, 123-36	4.1	58
615	Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6162-7	12.9	58
614	Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. <i>Acta Haematologica</i> , <b>2001</b> , 106, 57-68	2.7	58
613	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , <b>2016</b> , 127, 2693-700	2.2	57
612	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1874-1882	4.7	57
611	Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. <i>Future Oncology</i> , <b>2018</b> , 14, 1035-1047	3.6	56
610	Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3260-9	12.9	56
609	The emerging role of novel therapies for the treatment of relapsed myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2007</b> , 5, 149-62	7.3	56
608	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , <b>2007</b> , 20, 797-816	4.2	55
607	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. <i>Blood</i> , <b>2005</b> , 105, 4470-6	2.2	54
606	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1357-68	3.5	53

605	Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. <i>JAMA Oncology</i> , <b>2017</b> , 3, 980-988	13.4	53
604	Genetic variation associated with bortezomib-induced peripheral neuropathy. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 121-9	1.9	53
603	Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 428-37	4.5	53
602	Proteasome inhibition in hematologic malignancies. <i>Annals of Medicine</i> , <b>2004</b> , 36, 304-14	1.5	53
601	Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 438-45	4.5	52
600	Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. <i>Seminars in Hematology</i> , <b>2009</b> , 46, 166-75	4	52
599	Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. <i>Blood</i> , <b>2008</b> , 112, 4343-52	2.2	52
598	Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 865-74	12.9	51
597	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 314-9	7.1	50
596	Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. <i>Cancer Research</i> , <b>2014</b> , 74, 4458-69	10.1	50
595	Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. <i>Haematologica</i> , <b>2011</b> , 96, 1662-9	6.6	50
594	Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 472-80	4.5	49
593	Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. <i>British Journal of Haematology</i> , <b>2008</b> , 143, 511-9	4.5	49
592	Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 112-118	4.5	46
591	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , <b>2017</b> , 130, 1198-1204	2.2	46
590	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2380-2389	2.2	46
589	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e183267	13.4	45
588	The treatment of relapsed and refractory multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , <b>2007</b> , 2007, 317-23	3.1	45



587	Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 1175	2.2	45
586	Bortezomib: a novel therapy approved for multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , <b>2003</b> , 1, 596-600	0.6	45
585	Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. <i>Lancet Haematology</i> , <b>2020</b> , 7, e395-e407	14.6	44
584	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. <i>Leukemia Research</i> , <b>2013</b> , 37, 829-37	2.7	44
583	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 737-48	3.5	43
582	Melflufen - a peptidase-potentiated alkylating agent in clinical trials. <i>Oncotarget</i> , <b>2017</b> , 8, 66641-66655	3.3	43
581	Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 942-51	6.1	43
580	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 757-767	2.2	43
579	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. <i>British Journal of Haematology</i> , <b>2015</b> , 169, 843-50	4.5	42
578	Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTION recommendations. <i>Neurology</i> , <b>2018</b> , 91, 403-413	6.5	42
577	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , <b>2014</b> , 124, 3110-7	2.2	42
576	Lenalidomide in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 1165-73	3.5	42
575	Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1210-21	12.9	41
574	A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 41-51	4.5	41
573	Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. <i>Clinical Advances in Hematology and Oncology</i> , <b>2008</b> , 6, 755-60	0.6	41
572	APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. <i>Leukemia</i> , <b>2019</b> , 33, 426-438	10.7	40
571	Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. <i>Oral Oncology</i> , <b>2013</b> , 49, 977-983	4.4	40
570	Emerging therapies for multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , <b>2009</b> , 14, 99-127	3.7	40

569	Kidney disease associated with plasma cell dyscrasias. <i>Blood</i> , <b>2010</b> , 116, 1397-404	2.2	40
568	Novel biological therapies for the treatment of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , <b>2005</b> , 18, 619-34	4.2	40
567	A review of the proteasome inhibitor bortezomib in multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2004</b> , 5, 1321-31	4	40
566	Defibrotide for Treatment of Severe Venous Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1306-1312	4.7	40
565	Proteasome inhibition in the treatment of cancer. <i>Cell Cycle</i> , <b>2005</b> , 4, 290-6	4.7	40
564	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 571-582	4.5	39
563	Defibrotide for Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 997-1004	4.7	39
562	Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 370-6	2	39
561	Novel biologically based therapies for Waldenström's macroglobulinemia. <i>Seminars in Oncology</i> , <b>2003</b> , 30, 309-12	5.5	39
560	Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. <i>British Journal of Haematology</i> , <b>2003</b> , 121, 592-6	4.5	39
559	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. <i>Oncogene</i> , <b>2005</b> , 24, 3121-9	4.5	39
558	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 344-353	12.9	39
557	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 547-560	4.5	38
556	Marizomib for central nervous system-multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 2217-25	4.5	38
555	Guidelines for determination of the number of prior lines of therapy in multiple myeloma. <i>Blood</i> , <b>2015</b> , 126, 921-2	2.2	38
554	Proteasome inhibition as a new therapeutic principle in hematological malignancies. <i>Current Drug Targets</i> , <b>2006</b> , 7, 1341-7	3	38
553	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. <i>Lancet Haematology</i> , <b>2021</b> , 8, e45-e54	14.6	38
552	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 137	22.4	37

551	Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , <b>2012</b> , 5, 291-302	2.8	37
550	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. <i>Haematologica</i> , <b>2010</b> , 95, 1144-9	6.6	37
549	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2660-2	12.9	36
548	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , <b>2017</b> , 102, 1767-1775	6.6	36
547	Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2007</b> , 33, 373-88	5.3	36
546	Bortezomib-induced tumor lysis syndrome in multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , <b>2006</b> , 7, 233-5		36
545	Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. <i>Oligonucleotides</i> , <b>2006</b> , 16, 105-14		36
544	A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2004</b> , 10, 635-44	4.7	36
543	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , <b>2014</b> , 99, 1114-22	6.6	35
542	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 734-744	3.3	35
541	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , <b>2020</b> , 11, 2996	17.4	34
540	Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. <i>British Journal of Haematology</i> , <b>2015</b> , 171, 798-812	4.5	34
539	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , <b>2016</b> , 128, 675-675	2.2	34
538	A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 397-409	4.5	33
537	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors <b>1998</b> , 83, 409-414		33
536	A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. <i>Oncotarget</i> , <b>2016</b> , 7, 77326-77341	3.3	33
535	Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 711-20	4.5	33
534	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. <i>Therapeutic Advances in Hematology</i> , <b>2012</b> , 3, 253-65	5.7	32

533	The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. <i>Blood Coagulation and Fibrinolysis</i> , <b>2009</b> , 20, 627-34	1	32
532	The evolution and impact of therapy in multiple myeloma. <i>Medical Oncology</i> , <b>2010</b> , 27 Suppl 1, S1-6	3.7	32
531	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , <b>2020</b> , 7, e447-e455	14.6	32
530	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , <b>2021</b> , 22, e105-e118	21.7	32
529	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1949-1968	4.8	32
528	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 985	7.1	31
527	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. <i>Haematologica</i> , <b>2015</b> , 100, 100-6	6.6	31
526	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. <i>Blood</i> , <b>2019</b> , 134, 691-691	2.2	31
525	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , <b>2021</b> , 35, 562-572	10.7	31
524	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 8-17.e16	2	31
523	The use of defibrotide in blood and marrow transplantation. <i>Blood Advances</i> , <b>2018</b> , 2, 1495-1509	7.8	31
522	Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1448-1453	4.3	30
521	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 401-9	4.5	30
520	Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. <i>American Journal of Hematology</i> , <b>2007</b> , 82, 831-3	7.1	30
519	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Future Oncology</i> , <b>2005</b> , 1, 161-71	3.6	30
518	Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159. <i>Blood</i> , <b>2017</b> , 130, 741-741	2.2	30
517	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , <b>2019</b> , 33, 1736-1746	10.7	29
516	Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1951-1962	4.4	29

515	Pathological crystallization of human immunoglobulins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 13359-61	11.5	29
514	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. <i>Current Opinion in Oncology</i> , <b>2006</b> , 18, 598-608	4.2	29
513	Current use of monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 447-459	4.5	28
512	Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 1731-40	5.4	28
511	Novel therapies in the treatment of multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2009</b> , 7, 947-60	7.3	28
510	A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. <i>Therapeutics and Clinical Risk Management</i> , <b>2008</b> , 4, 129-36	2.9	28
509	Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. <i>Cancer Research</i> , <b>2004</b> , 64, 8746-53	10.1	28
508	Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).. <i>Blood</i> , <b>2004</b> , 104, 336-336	2.2	28
507	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 485-495	4.4	28
506	How I treat the young patient with multiple myeloma. <i>Blood</i> , <b>2018</b> , 132, 1114-1124	2.2	28
505	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 137-144	4.7	27
504	Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3955-61	12.9	27
503	Fatty acid synthase is a novel therapeutic target in multiple myeloma. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 659-71	4.5	27
502	p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. <i>Blood</i> , <b>2017</b> , 129, 1308-1319	2.2	26
501	Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. <i>Blood</i> , <b>2012</b> , 119, e131-8	2.2	26
500	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Cancer Management and Research</i> , <b>2012</b> , 4, 253-68	3.6	26
499	A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. <i>Proteomics</i> , <b>2011</b> , 11, 1391-402	4.8	26
498	Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenström's Macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 694-702	1.9	26

497	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2009</b> , 147, 531-4	4.5	26
496	Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2010</b> , 8 Suppl 1, S4-S12	7.3	26
495	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. <i>Blood</i> , <b>2020</b> , 136, 39-39	2.2	26
494	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 39	7	25
493	Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 433-446	4.5	25
492	Management of myeloma-associated renal dysfunction in the era of novel therapies. <i>Expert Review of Hematology</i> , <b>2012</b> , 5, 51-66; quiz 67-8	2.8	25
491	Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503). <i>Blood</i> , <b>2015</b> , 126, 507-507	2.2	25
490	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , <b>2020</b> , 136, 2513-2523	2.2	25
489	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , <b>2018</b> , 15, 1033-1052	1.52	25
488	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 229-237	2.8	24
487	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1244-1253	7.1	24
486	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , <b>2018</b> , 32, 1838-1841	10.7	24
485	Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 88 Suppl 1, S36-44	7	24
484	Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.. <i>Blood</i> , <b>2006</b> , 108, 405-405	2.2	24
483	Monoclonal antibodies in myeloma. <i>Clinical Advances in Hematology and Oncology</i> , <b>2015</b> , 13, 599-609	0.6	24
482	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , <b>2015</b> , 11, 1153-68	3.6	23
481	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 821-830	4.5	23
480	Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 113-124	3.8	23

479	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2833-2838	1.9	23
478	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 384-393	8	23
477	In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. <i>British Journal of Haematology</i> , <b>2009</b> , 147, 672-6	4.5	23
476	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 2308-15	1.9	23
475	Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. <i>Leukemia and Lymphoma</i> , <b>1998</b> , 31, 267-77	1.9	23
474	New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 734-44	3.3	23
473	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , <b>2020</b> , 7, e61-e72	14.6	23
472	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 495-503	4.5	23
471	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 231-244	4.5	23
470	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2011</b> , 118, 302-302	2.2	22
469	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , <b>2015</b> , 126, 28-28	2.2	22
468	First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8500-8500	2.2	22
467	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , <b>2021</b> , 22, 142-154	21.7	22
466	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 746-751	7.1	21
465	Selinexor for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 399-408	4	21
464	Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Venocclusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 100-110	4.7	21
463	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , <b>2011</b> , 4, 51-60	2.8	21
462	Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 420-32	4.5	21

461	Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.. <i>Blood</i> , <b>2005</b> , 106, 2547-2547	2.2	21
460	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study. <i>Blood</i> , <b>2008</b> , 112, 92-92	2.2	21
459	Optimizing bortezomib treatment in patients with relapsed multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , <b>2006</b> , 4, 4-5; discussion 8; suppl 13	0.6	21
458	Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. <i>Leukemia</i> , <b>2019</b> , 33, 2208-2226	10.7	20
457	Best treatment strategies in high-risk multiple myeloma: navigating a gray area. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2125-32	2.2	20
456	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , <b>2014</b> , 2014, 255-61	3.1	20
455	Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. <i>British Journal of Haematology</i> , <b>2012</b> , 159, 340-51	4.5	20
454	Management of relapsed and relapsed/refractory multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2011</b> , 9, 1209-16	7.3	20
453	A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Preliminary Results.. <i>Blood</i> , <b>2005</b> , 106, 1565-1565	2.2	20
452	First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. <i>Blood</i> , <b>2016</b> , 128, 1148-1148	2.2	20
451	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 106	7	20
450	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 43-51	4.5	20
449	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 942-945	4.4	19
448	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 35-48	3.8	19
447	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e27269	3	19
446	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , <b>2017</b> , 117, 185-191	10.2	19
445	Management of relapsed multiple myeloma after autologous stem cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 793-8	4.7	19
444	A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , <b>2011</b> , 86, 573-8	7.1	19



443	A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).. <i>Blood</i> , <b>2006</b> , 108, 406-406	2.2	19
442	Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 2123-2123	2.2	19
441	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3107-3118	2.2	19
440	Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. <i>Journal of Geriatric Oncology</i> , <b>2019</b> , 10, 486-489	3.6	19
439	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 478-486	12.9	19
438	New treatments for multiple myeloma. <i>Oncology</i> , <b>2005</b> , 19, 1781-92; discussion 1792, 1795-7	1.8	19
437	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 529-538	6.2	18
436	Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4206-4214	12.9	18
435	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 555-562	2	18
434	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , <b>2021</b> , 35, 1722-1731 <sup>10.7</sup>	10.7	18
433	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2430-2442	2.2	18
432	New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. <i>Journal of Blood Medicine</i> , <b>2017</b> , 8, 107-121	2.3	17
431	Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. <i>British Journal of Haematology</i> , <b>2011</b> , 154, 755-62	4.5	17
430	Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results. <i>Blood</i> , <b>2015</b> , 126, 375-375	2.2	17
429	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study). <i>Blood</i> , <b>2015</b> , 126, 4228-4228	2.2	17
428	Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 1133-1141	5.9	17
427	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5688-5695	12.9	17
426	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , <b>2020</b> , 13, 421-433	2.8	16

425	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 271-275	4.5	16
424	Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 127-31	4.5	16
423	Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. <i>British Journal of Haematology</i> , <b>2013</b> , 160, 351-8	4.5	16
422	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. <i>Targeted Oncology</i> , <b>2017</b> , 12, 643-654	5	16
421	Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 885-898	4.2	16
420	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. <i>International Journal of Hematologic Oncology</i> , <b>2017</b> , 6, 75-93	1	16
419	Combination of a Selective HSP90 $\alpha$ Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143847	3.7	16
418	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2020</b> , 136, 16-17	2.2	16
417	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. <i>Blood</i> , <b>2013</b> , 122, 535-535	2.2	16
416	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. <i>Core Evidence</i> , <b>2010</b> , 4, 215-45	4.9	16
415	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , <b>2021</b> , 137, 3616-3628	2.2	16
414	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , <b>2021</b> , 106, 1182-1187	6.6	16
413	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 199-206	3.8	15
412	Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. <i>Blood</i> , <b>2012</b> , 120, 73-73	2.2	15
411	Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. <i>Blood</i> , <b>2014</b> , 124, 3453-3453	2.2	15
410	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , <b>2014</b> , 124, 82-82	2.2	15
409	ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD $\alpha$ ) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). <i>Blood</i> , <b>2015</b> , 126, 3040-3040 <sup>2</sup>	2	15
408	Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PvD) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8001-8001	2.2	15

407	Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. <i>Blood Cancer Discovery</i> , <b>2021</b> , 2, 468-483	7	15
406	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 1	3.9	15
405	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. <i>Cell Reports</i> , <b>2021</b> , 34, 108532	10.6	15
404	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 756-763	4.5	14
403	Novel targeted agents in the treatment of multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , <b>2014</b> , 28, 903-25	3.1	14
402	Novel therapies in myeloma. <i>Current Opinion in Hematology</i> , <b>2007</b> , 14, 609-15	3.3	14
401	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , <b>2014</b> , 2014, 255-261	3.1	14
400	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 804-804	2.2	14
399	Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.. <i>Blood</i> , <b>2007</b> , 110, 1164-1164	2.2	14
398	Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. <i>Blood</i> , <b>2007</b> , 110, 1165-1165	2.2	14
397	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , <b>2013</b> , 122, 759-759	2.2	14
396	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	14
395	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 475-479	4.5	14
394	Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 756-771	4.5	13
393	Recent advances in the treatment of Multiple Myeloma. <i>Current Pharmaceutical Biotechnology</i> , <b>2006</b> , 7, 381-93	2.6	13
392	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (Rvd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , <b>2020</b> , 136, 45-46	2.2	13
391	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 3483-3483	2.2	13
390	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 976-976	2.2	13

389	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 118-123	1.9	12
388	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 66-74	4.5	12
387	Use of defibrotide in the treatment and prevention of veno-occlusive disease. <i>Expert Review of Hematology</i> , <b>2009</b> , 2, 365-76	2.8	12
386	A Phase 1 Trial of Lenalidomide (REVLIMID <sup>®</sup> ) with Bortezomib (VELCADE <sup>®</sup> ) in Relapsed and Refractory Multiple Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 365-365	2.2	12
385	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. <i>Blood</i> , <b>2008</b> , 112, 93-93	2.2	12
384	Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results From the Phase III International Myeloma Working Group Trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 471-477	2.2	12
383	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , <b>2012</b> , 120, 202-202	2.2	12
382	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , <b>2015</b> , 126, 395-395	2.2	12
381	A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8004-8004	2.2	12
380	Isatuximab for the treatment of relapsed/refractory multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 1395-1404	5.4	12
379	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 496-507	4.5	12
378	Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥ lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 628-636	4.5	12
377	Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 66-79	4.5	11
376	Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 212-21	4.5	11
375	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2007</b> , 7, 551-66	3.5	11
374	Proteasome inhibition as a therapeutic strategy for hematologic malignancies. <i>Expert Review of Anticancer Therapy</i> , <b>2005</b> , 5, 465-76	3.5	11
373	Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. <i>Blood</i> , <b>2009</b> , 114, 127-127	2.2	11
372	Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.. <i>Blood</i> , <b>2009</b> , 114, 654-654	2.2	11

371	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2013</b> , 122, 1969-1969	2.2	11
370	Distinctive Biomarker Features in The Endotheliopathy of COVID-19 and Septic Syndromes. <i>Shock</i> , <b>2021</b> ,	3.4	11
369	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , <b>2019</b> , 186, e35-e39	4.5	10
368	The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 692-703	4.5	10
367	Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1342-1349	4.7	10
366	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 351-357	2	10
365	Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 1291-301	5.4	10
364	The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. <i>European Journal of Haematology</i> , <b>2012</b> , 88, 446-9	3.8	10
363	Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. <i>Blood</i> , <b>2013</b> , 121, 858	2.2	10
362	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.. <i>Lancet Oncology, The</i> , <b>2022</b> ,	21.7	10
361	Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2008</b> , 112, 3691-3691	2.2	10
360	Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , <b>2008</b> , 112, 3696-3696	2.2	10
359	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. <i>Blood</i> , <b>2009</b> , 114, 2878-2878	2.2	10
358	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2014</b> , 124, 4764-4764	2.2	10
357	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). <i>Blood</i> , <b>2015</b> , 126, 1827-1827	2.2	10
356	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 23-23	2.2	10
355	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , <b>2015</b> , 126, 3036-3036	2.2	10
354	Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 1069-1078	5.9	10

353	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. <i>Leukemia Research</i> , <b>2021</b> , 104, 106576	2.7	10
352	Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 82-8	4.5	10
351	Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, e39-45	2	9
350	Maintenance and continuous therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 751-764	3.5	9
349	Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e175-9	2.2	9
348	Emerging drugs in multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , <b>2007</b> , 12, 155-63	3.7	9
347	An update of novel therapeutic approaches for multiple myeloma. <i>Current Treatment Options in Oncology</i> , <b>2004</b> , 5, 227-38	5.4	9
346	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-2004. A 40-year-old man with a large tumor of the skull. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 2637-45	59.2	9
345	OP-106 Horizon [Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. <i>Blood</i> , <b>2018</b> , 132, 600-600	2.2	9
344	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , <b>2018</b> , 132, 598-598	2.2	9
343	ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). <i>Blood</i> , <b>2019</b> , 134, 3124-3124	2.2	9
342	Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.. <i>Blood</i> , <b>2007</b> , 110, 1170-1170	2.2	9
341	Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.. <i>Blood</i> , <b>2007</b> , 110, 1179-1179	2.2	9
340	Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. <i>Blood</i> , <b>2010</b> , 116, 621-621	2.2	9
339	Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response. <i>Blood</i> , <b>2011</b> , 118, 1881-1881	2.2	9
338	A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 1976-1976	2.2	9
337	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 708-718	7.18	9
336	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 120-131	4.5	9

335	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E5-E8 <sup>7.1</sup>	7.1	9
334	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. <i>Blood Reviews</i> , <b>2021</b> , 49, 100808	11.1	9
333	Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. <i>Oncology</i> , <b>2010</b> , 24, 22-9	1.8	9
332	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 494-503	3.8	8
331	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. <i>Cells</i> , <b>2020</b> , 9,	7.9	8
330	Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 933-939	2.8	8
329	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 1975-1985	4	8
328	Novel biologically based therapies for multiple myeloma. <i>International Journal of Hematology</i> , <b>2002</b> , 76 Suppl 1, 340-1	2.3	8
327	Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3138-40	2.2	8
326	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , <b>2012</b> , 120, 450-450	2.2	8
325	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , <b>2014</b> , 124, 31-31	2.2	8
324	Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8014-8014	2.2	8
323	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , <b>2021</b> , 17, 1987-2003	3.6	8
322	A clinical perspective on plasma cell leukemia; current status and future directions. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 23	7	8
321	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , <b>2018</b> , 32, 2032-2036	10.7	7
320	Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e353-e354	2	7
319	Clinical translation in multiple myeloma: from bench to bedside. <i>Seminars in Oncology</i> , <b>2013</b> , 40, 549-53	5.5	7
318	Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 1014-6	21.7	7

317	Re: When you look matters: the effect of assessment schedule on progression-free survival. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 373	9.7	7
316	Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2000</b> , 45, 239-46	3.5	7
315	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.. <i>Lancet Haematology,the</i> , <b>2022</b> ,	14.6	7
314	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , <b>2019</b> , 134, 3125-3125	2.2	7
313	Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2019</b> , 134, 1857-1857	2.2	7
312	Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , <b>2004</b> , 104, 1503-1503	2.2	7
311	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 4217-4217	2.2	7
310	Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 4220-4220	2.2	7
309	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8519-8519	2.2	7
308	Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 529-539	4.7	7
307	Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , <b>2020</b> , 1, 94-102	0.9	6
306	The challenge of cross-trial comparisons using limited data. <i>Haematologica</i> , <b>2014</b> , 99, e145-6	6.6	6
305	The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. <i>European Journal of Haematology</i> , <b>2012</b> , 88, 1-7	3.8	6
304	Toward a new therapeutic backbone in myeloma. <i>Blood</i> , <b>2007</b> , 109, 2672-2673	2.2	6
303	Emerging trends in the clinical use of bortezomib in multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , <b>2005</b> , 6, 84-8		6
302	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , <b>2018</b> , 132, 749-749	2.2	6
301	High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 4-5	2.2	6
300	Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , <b>2006</b> , 108, 3532-3532		6



299	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2008</b> , 112, 832-832	2.2	6
298	Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.. <i>Blood</i> , <b>2009</b> , 114, 2890-2890	2.2	6
297	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2010</b> , 116, 3952-3952	2.2	6
296	Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 4772-4772	2.2	6
295	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. <i>Blood</i> , <b>2016</b> , 128, 3326-3326	2.2	6
294	Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8014-8014	2.2	6
293	CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002. <i>Blood</i> , <b>2021</b> , 138, 2731-2731	2.2	6
292	Proteasome inhibitors as therapeutics. <i>Essays in Biochemistry</i> , <b>2005</b> , 41, 205-218	7.6	6
291	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 59	22.4	6
290	Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. <i>Leukemia</i> , <b>2021</b> ,	10.7	6
289	Treatment of Relapsed/Refractory Multiple Myeloma. <i>Cancer Treatment and Research</i> , <b>2016</b> , 169, 169-194	25	6
288	Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e33	2	6
287	Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 1105-1109	4.5	6
286	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 20	7	6
285	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 581-591	4.5	6
284	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, S249-S250	2	6
283	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1595-1603	7.1	6
282	Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 583-587	4.5	5

281	Evolving strategies in the initial treatment of multiple myeloma. <i>Seminars in Oncology</i> , <b>2013</b> , 40, 592-601.	5.5	5
280	Bortezomib in the management of multiple myeloma. <i>Cancer Management and Research</i> , <b>2009</b> , 1, 107-173.	6	5
279	Does maintenance therapy with thalidomide benefit patients with multiple myeloma?. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 394-5		5
278	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 3169-3169	2.2	5
277	Defibrotide (DF) Targets Tumor-Microenvironmental Interactions and Sensitizes Multiple Myeloma and Solid Tumor Cells to Cytotoxic Chemotherapeutics.. <i>Blood</i> , <b>2004</b> , 104, 286-286	2.2	5
276	Targeting Bcl-2 as Therapy for Multiple Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 109-109	2.2	5
275	A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , <b>2006</b> , 108, 3582-3582	2.2	5
274	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. <i>Blood</i> , <b>2009</b> , 114, 132-132	2.2	5
273	Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).. <i>Blood</i> , <b>2010</b> , 116, 3481-3481	2.2	5
272	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. <i>Blood</i> , <b>2010</b> , 116, 990-990	2.2	5
271	Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. <i>Blood</i> , <b>2011</b> , 118, 301-301	2.2	5
270	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORTZ). <i>Blood</i> , <b>2015</b> , 126, 3055-3055	2.2	5
269	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study). <i>Blood</i> , <b>2015</b> , 126, 3055-3055	2.2	5
268	Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8526-8526	2.2	5
267	HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e20570-e20570	2.2	5
266	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , <b>2021</b> , 35, 3526-3533	10.7	5
265	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 58-64.e1	3.3	5
264	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1120-1130	7.1	5

263	Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 344-348	4.7	4
262	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 35-46	3.8	4
261	Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 29	7	4
260	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1850-1859	1.9	4
259	The comprehensive clinical management of multiple myeloma and related-plasma cell disorders. <i>Expert Review of Hematology</i> , <b>2014</b> , 7, 1-3	2.8	4
258	Improving the therapeutic index in myeloma. <i>Blood</i> , <b>2010</b> , 116, 4733-4	2.2	4
257	Management of relapsed and relapsed refractory myeloma. <i>Hematology/Oncology Clinics of North America</i> , <b>2007</b> , 21, 1175-215, x	3.1	4
256	Hemostatic complications of hematopoietic stem cell transplantation: from hemorrhage to microangiopathies and VOD. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2003</b> , 33 Suppl 1, 50-3		4
255	Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104). <i>Blood</i> , <b>2018</b> , 132, 4737-4737	2.2	4
254	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , <b>2019</b> , 134, 3140-3140	2.2	4
253	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis. <i>Blood</i> , <b>2020</b> , 136, 15-17	2.2	4
252	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2008</b> , 112, 3700-3700	2.2	4
251	A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population. <i>Blood</i> , <b>2010</b> , 116, 1951-1951	2.2	4
250	Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). <i>Blood</i> , <b>2011</b> , 118, 2933-2933	2.2	4
249	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 303-303	2.2	4
248	PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 1852-1852	2.2	4
247	Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (Btz). <i>Blood</i> , <b>2012</b> , 120, 4053-4053	2.2	4
246	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 2120-2120	2.2	4

245	Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 4256-4256	2.2	4
244	Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8588-8588	2.2	4
243	Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8038-8038	2.2	4
242	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (Rvd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. <i>Blood</i> , <b>2021</b> , 138, 79-79	2.2	4
241	ICARIA-MM study: efficacy analysis according to prior lines of treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e245-e246	2	4
240	Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , <b>2006</b> , 4, 1; discussion 8; suppl 13	0.6	4
239	Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Opinion on Orphan Drugs</i> , <b>2019</b> , 7, 337-347	1.1	3
238	Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF- $\kappa$ B pathway activation. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 274-285	3.8	3
237	Advances in the treatment of monoclonal gammopathies: The emerging role of targeted therapy in plasma cell dyscrasias. <i>Biologics: Targets and Therapy</i> , <b>2008</b> , 2, 419-31	4.4	3
236	Can thalidomide improve outcome in patients with multiple myeloma?. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 590-1		3
235	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. <i>British Journal of Haematology</i> , <b>2006</b> , 132, 698-704	4.5	3
234	Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab. <i>Blood</i> , <b>2020</b> , 136, 1888-1888	2.2	3
233	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis. <i>Blood</i> , <b>2020</b> , 136, 41-43	2.2	3
232	IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.. <i>Blood</i> , <b>2004</b> , 104, 2403-2403	2.2	3
231	Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.. <i>Blood</i> , <b>2004</b> , 104, 2404-2404	2.2	3
230	PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo.. <i>Blood</i> , <b>2005</b> , 106, 247-247	2.2	3
229	Lack of Response to Vaccination in MGUS and Stable Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 1852-1852	2.2	3
228	Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.. <i>Blood</i> , <b>2009</b> , 114, 1871-1871	2.2	3

227	Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. <i>Blood</i> , <b>2010</b> , 116, 3051-3051	2.2	3
226	Safety of Defibrotide (DF) In Stem Cell Transplant (SCT) Patients (Pts).. <i>Blood</i> , <b>2010</b> , 116, 3482-3482	2.2	3
225	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. <i>Blood</i> , <b>2010</b> , 116, 986-986	2.2	3
224	Defibrotide (DF) in the Treatment of Hepatic VenO-occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol. <i>Blood</i> , <b>2011</b> , 118, 487-487	2.2	3
223	Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2012</b> , 120, 4039-4039	2.2	3
222	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes. <i>Blood</i> , <b>2012</b> , 120, 4072-4072	2.2	3
221	Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 1970-1970	2.2	3
220	Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , <b>2013</b> , 122, 4402-4402	2.2	3
219	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2014</b> , 124, 3081-3081	2.2	3
218	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. <i>Blood</i> , <b>2015</b> , 126, 3031-3031	2.2	3
217	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2016</b> , 128, 243-243	2.2	3
216	Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic VenO-occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study. <i>Blood</i> , <b>2016</b> , 128, 66-66	2.2	3
215	Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. <i>Cancer Science</i> , <b>2020</b> , 111, 2116-2122	6.9	3
214	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. <i>Blood</i> , <b>2021</b> , 138, 162-162	2.2	3
213	JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.. <i>Blood</i> , <b>2004</b> , 104, 3413-3413	2.2	3
212	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , <b>2017</b> , 130, 902-902	2.2	3
211	Resistance to Proteasome Inhibitors in Multiple Myeloma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , <b>2014</b> , 47-80	0.3	3
210	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.. <i>Blood</i> , <b>2008</b> , 112, 1716-1716	2.2	3

209	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 797-803 <sup>2</sup>	3
208	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , <b>2021</b> , 14, 697-706	2.8 3
207	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in -Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6432-6444	12.9 3
206	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E423-E427 <sup>7.1</sup>	3
205	IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. <i>Oncology</i> , <b>2013</b> , 27, 803-4, 806	1.8 3
204	Extramedullary disease in multiple myeloma: a systematic literature review.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 45	7 3
203	Defibrotide for the Treatment of Severe Hepatic Venous Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, S110	4.7 2
202	The treatment of multiple myeloma patients not eligible for asct. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2010</b> , 2, e2010009	3.2 2
201	Conflicts of interest, authorship, and disclosures in industry-related scientific publications. <i>Mayo Clinic Proceedings</i> , <b>2010</b> , 85, 197-9; author reply 201-4	6.4 2
200	Reply to C.A. Dasanu et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2294-2296	2.2 2
199	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. <i>Nature Precedings</i> , <b>2008</b> ,	2
198	Emerging Therapies for Multiple Myeloma. <i>American Journal of Cancer</i> , <b>2006</b> , 5, 141-153	2
197	HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents. <i>Blood</i> , <b>2020</b> , 136, 2-4	2.2 2
196	The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data. <i>Blood</i> , <b>2018</b> , 132, 1967-1967	2.2 2
195	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis. <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2 2
194	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients. <i>Blood</i> , <b>2020</b> , 136, 44-46	2.2 2
193	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application. <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2 2
192	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. <i>Blood</i> , <b>2004</b> , 104, 2405-2405	2.2 2

191	Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.. <i>Blood</i> , <b>2004</b> , 104, 751-751	2.2	2
190	Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 1571-1571	2.2	2
189	Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.. <i>Blood</i> , <b>2006</b> , 108, 3468-3468.2	2.2	2
188	Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.. <i>Blood</i> , <b>2006</b> , 108, 3485-3485	2.2	2
187	Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.. <i>Blood</i> , <b>2007</b> , 110, 1185-1185	2.2	2
186	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , <b>2007</b> , 110, 4496-4496	2.2	2
185	A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models.. <i>Blood</i> , <b>2008</b> , 112, 1719-1719	2.2	2
184	Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2010</b> , 116, 1943-1943	2.2	2
183	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. <i>Blood</i> , <b>2010</b> , 116, 3803-3803	2.2	2
182	Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol. <i>Blood</i> , <b>2010</b> , 116, 906-906	2.2	2
181	Blockade of XBP1 Splicing by Inhibition of IRE1 $\beta$ s a Promising Therapeutic Option in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 133-133	2.2	2
180	Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , <b>2011</b> , 118, 479-479	2.2	2
179	Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study. <i>Blood</i> , <b>2012</b> , 120, 4052-4052	2.2	2
178	Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 1869-1869	2.2	2
177	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , <b>2015</b> , 126, 4246-4246	2.2	2
176	Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells.. <i>Blood</i> , <b>2007</b> , 110, 1519-1519	2.2	2
175	The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone. <i>Blood</i> , <b>2019</b> , 134, 3487-3487	2.2	2
174	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor Microenvironment Interactions.. <i>Blood</i> , <b>2010</b> , 116, 1574-1574	2.2	2

173	Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 55	7	2
172	ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM) Optimal dose, updated efficacy and safety results.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8037-8037	2.2	2
171	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , <b>2021</b> , 25, 423-433	6.4	2
170	Dual inhibition of oncogenic targets for B-cell malignancies. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 547-9	21.7	2
169	Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e352-e353	2	2
168	Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 88.e1-88.e6		2
167	Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. <i>EJHaem</i> , <b>2021</b> , 2, 48-55	0.9	2
166	Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation. <i>Oncology</i> , <b>2003</b> , 17, 1063-5	1.8	2
165	New therapies for the treatment of multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , <b>2005</b> , 3, 345-6	0.6	2
164	Efficacy and Tolerability of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Standard Twice-Weekly Bortezomib and Dexamethasone in Previously Treated Multiple Myeloma with Renal Impairment: Subgroup Analysis from the BOSTON Study. <i>American Journal of Hematology</i> , <b>2021</b> ,	7.1	2
163	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , <b>2018</b> , 73-96	0	1
162	Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1078-9	4.7	1
161	Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit. <i>Expert Opinion on Orphan Drugs</i> , <b>2015</b> , 3, 1491-1501	1.1	1
160	Management Strategies for Relapsed Multiple Myeloma. <i>American Journal of Cancer</i> , <b>2006</b> , 5, 393-409		1
159	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , <b>2020</b> , 136, 6-8	2.2	1
158	Antibody-drug conjugate therapies in multiple myeloma What's next on the horizon?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 617-626	2.5	1
157	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. <i>Blood</i> , <b>2018</b> , 132, 1960-1960	2.2	1
156	Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1. <i>Blood</i> , <b>2019</b> , 134, 1839-1839	2.2	1



155	A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action. <i>Blood</i> , <b>2020</b> , 136, 34-34	2.2	1
154	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. <i>Blood</i> , <b>2004</b> , 104, 2456-2456	2.2	1
153	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. <i>Blood</i> , <b>2005</b> , 106, 3380-3380	2.2	1
152	Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone.. <i>Blood</i> , <b>2005</b> , 106, 4447-4447	2.2	1
151	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. <i>Blood</i> , <b>2006</b> , 108, 3460-3460	2.2	1
150	Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. <i>Blood</i> , <b>2007</b> , 110, 284-284	2.2	1
149	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , <b>2007</b> , 110, 4493-4493	2.2	1
148	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. <i>Blood</i> , <b>2008</b> , 112, 1011-1011	2.2	1
147	Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma. <i>Blood</i> , <b>2008</b> , 112, 3662-3662	2.2	1
146	A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism. <i>Blood</i> , <b>2010</b> , 116, 3007-3007	2.2	1
145	Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , <b>2010</b> , 116, 3013-3013	2.2	1
144	A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma [Preliminary Safety Data. <i>Blood</i> , <b>2011</b> , 118, 1873-1873	2.2	1
143	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 1874-1874	2.2	1
142	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , <b>2011</b> , 118, 2705-2705	2.2	1
141	Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2011</b> , 118, 2706-2706	2.2	1
140	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , <b>2011</b> , 118, 3966-3966	2.2	1
139	Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,. <i>Blood</i> , <b>2011</b> , 118, 3968-3968	2.2	1
138	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. <i>Blood</i> , <b>2012</b> , 120, 4070-4070	2.2	1

137	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients. <i>Blood</i> , <b>2014</b> , 124, 1138-1138	2.2	1
136	Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method. <i>Blood</i> , <b>2014</b> , 124, 2036-2036 <sup>2,2</sup>	2.2	1
135	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , <b>2014</b> , 124, 638-638	2.2	1
134	A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism. <i>Blood</i> , <b>2015</b> , 126, 3000-3000	2.2	1
133	Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival. <i>Blood</i> , <b>2015</b> , 126, 3029-3029	2.2	1
132	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. <i>Blood</i> , <b>2015</b> , 126, 737-737	2.2	1
131	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 2122-2122	2.2	1
130	CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myeloma. Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8837-8837	2.2	1
129	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 19, 734-744	3.3	1
128	Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 169	7	1
127	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. <i>Nature Cell Biology</i> , <b>2021</b> , 23, 1199-1211	23.4	1
126	TGF- $\beta$ Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.. <i>Blood</i> , <b>2004</b> , 104, 2355-2355	2.2	1
125	The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.. <i>Blood</i> , <b>2006</b> , 108, 3452-3452	2.2	1
124	In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway.. <i>Blood</i> , <b>2007</b> , 110, 540-540	2.2	1
123	Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.. <i>Blood</i> , <b>2007</b> , 110, 1509-1509	2.2	1
122	Pomalidomide, bortezomib, and dexamethasone (Pvd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e20562-e20562	2.2	1
121	Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation. <i>Pediatric Oncology</i> , <b>2014</b> , 77-102	0.5	1
120	Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management <b>2011</b> , 95-105		1

119	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 27-27	2.2	1
118	Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 2846-2846		1
117	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenstro m's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. <i>Blood</i> , <b>2010</b> , 116, 2988-2988	2.2	1
116	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 752-765	2	1
115	The Future of Myeloma Therapy: One Size Does Not Fit All. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 295-6	3.1	1
114	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , <b>2021</b> , 17, 4797-4812	3.6	1
113	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , <b>2021</b> , 21, 993	4.8	1
112	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISM by clinical characteristics. <i>European Journal of Haematology</i> , <b>2022</b> , 108, 73-83	3.8	1
111	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2889-2896	4.4	1
110	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors <b>1998</b> , 83, 409		1
109	MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. <i>Oncology</i> , <b>2011</b> , 25, 594, 596	1.8	1
108	IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. <i>International Journal of Dermatology</i> , <b>2017</b> , 56, 1058-1060	1.7	0
107	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis. <i>Blood</i> , <b>2020</b> , 136, 27-29	2.2	0
106	Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 25-26	2.2	0
105	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 3398-3398	2.2	0
104	COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , <b>2021</b> , 138, 3801-3801	2.2	0
103	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. <i>Blood</i> , <b>2021</b> , 138, 2852-2852	2.2	0
102	Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 1613-1613	2.2	0

101	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , <b>2021</b> , 138, 3793-3793	2.2	0
100	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. <i>Blood</i> , <b>2018</b> , 132, 1981-1981	2.2	0
99	SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis. <i>Blood</i> , <b>2014</b> , 124, 3441-3441	2.2	0
98	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. <i>Blood</i> , <b>2010</b> , 116, 1963-1963	2.2	0
97	Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: Defibrotide as an endothelium-protective, targeted therapy. <i>EJHaem</i> , <b>2021</b> , 2, 680	0.9	0
96	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 63	7	0
95	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , <b>2014</b> , 2, 1089-1108	1.1	
94	Treatment of Multiple Myeloma <b>2014</b> , 358-365		
93	Treatment of relapsed/refractory myeloma 144-166		
92	A new standard of care in newly diagnosed multiple myeloma. <i>Lancet, The</i> , <b>2010</b> , 376, 2043-4	40	
91	Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9, S40-S42		
90	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Targeted Oncology</i> , <b>2008</b> , 3, 19-29	5	
89	The emerging role of novel therapeutic agents in the management of patients with multiple myeloma. <i>Community Oncology</i> , <b>2006</b> , 3, 575-582		
88	Proteasome inhibition. <i>American Journal of Cancer</i> , <b>2004</b> , 3, 271-279		
87	Proteasome inhibition as an anticancer target. <i>Nature Reviews Drug Discovery</i> , <b>2005</b> , 4, 698-698	64.1	
86	TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment. <i>Blood</i> , <b>2020</b> , 136, 31-31	2.2	
85	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations. <i>Blood</i> , <b>2020</b> , 136, 20-22	2.2	
84	Variation in the Treatment of Multiple Myeloma in the Real World. <i>Blood</i> , <b>2020</b> , 136, 43-44	2.2	

83	Melflufen A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Oncology &amp; Hematology Review</i> , <b>2020</b> , 16, 12	0.1
82	Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in	2.2
81	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses. <i>Blood</i> , <b>2021</b> , 138, 2732-2732	2.2
80	OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis. <i>Blood</i> , <b>2021</b> , 138, 4780-4780	2.2
79	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status. <i>Blood</i> , <b>2021</b> , 138, 4779-4779	2.2
78	Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 4969-4969	2.2
77	Sinusoidal Obstruction Syndrome/Hepatic Venous Occlusive Disease <b>2022</b> , 143-163	
76	Reply to G. R. Mohyuddin et al and A. Garfall et al. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2102081	2.2
75	Hepatic Venous Occlusive Disease <b>2004</b> , 297-314	
74	Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.. <i>Blood</i> , <b>2004</b> , 104, 1498-1498	2.2
73	Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. <i>Blood</i> , <b>2004</b> , 104, 2401-2401	2.2
72	Bortezomib Targets Multiple Myeloma Endothelial Cells.. <i>Blood</i> , <b>2004</b> , 104, 4903-4903	2.2
71	Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500K Single Nucleotide Polymorphism Array Analysis.. <i>Blood</i> , <b>2005</b> , 106, 1551-1551	2.2
70	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. <i>Blood</i> , <b>2005</b> , 106, 5150-5150	2.2
69	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. <i>Blood</i> , <b>2005</b> , 106, 627-627	2.2
68	Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma.. <i>Blood</i> , <b>2006</b> , 108, 3080-3080	2.2
67	Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.. <i>Blood</i> , <b>2006</b> , 108, 3396-3396	2.2
66	Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw.. <i>Blood</i> , <b>2006</b> , 108, 3591-3591	2.2

- 65 Novel Therapeutic Options for the Treatment of Relapsed and Relapsed, Refractory Myeloma. *Translational Medicine Series*, **2007**, 169-196
- 64 Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.. *Blood*, **2007**, 110, 2524-2524 2.2
- 63 Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.. *Blood*, **2007**, 110, 3507-3507 2.2
- 62 Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. *Blood*, **2007**, 110, 4494-4494 2.2
- 61 The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma **2008**, 291-308
- 60 The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma **2008**, 239-252
- 59 Hepatic Venno-Occlusive Disease **2008**, 467-493
- 58 Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen. *Blood*, **2018**, 132, 3234-3234 2.2
- 57 A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. *Blood*, **2018**, 132, 3263-3263 2.2
- 56 Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation [Results from the Tourmaline-MM1 Study. *Blood*, **2018**, 132, 473-473 2.2
- 55 CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. *Blood*, **2018**, 132, 1367-1367 2.2
- 54 Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2019**, 37, 8043-8043 2.2
- 53 Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degradors of Oncoproteins. *Blood*, **2019**, 134, 318-318 2.2
- 52 TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA46-63
- 51 Mimicking Myeloma Niche Ex Vivo. *Blood*, **2014**, 124, 2076-2076 2.2
- 50 Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. *Blood*, **2014**, 124, 3404-3404 2.2
- 49 Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Venno-Occlusive Disease. *Blood*, **2014**, 124, 2470-2470 2.2
- 48 Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. *Blood*, **2014**, 124, 2070-2070 2.2

- 47 Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide. *Blood*, **2015**, 126, 4253-4253 2.2
- 46 Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study. *Blood*, **2015**, 126, 5322-5322 2.2
- 45 Targeting Replicative Stress to Treat Hematological Disorders. *Blood*, **2015**, 126, 2419-2419 2.2
- 44 IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. *Blood*, **2016**, 128, 3276-3276 2.2
- 43 Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2016**, 128, 2134-2134 2.2
- 42 Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigen Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers. *Blood*, **2016**, 128, 5689-5689 2.2
- 41 A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. *Blood*, **2016**, 128, 5815-5815 2.2
- 40 Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. *Blood*, **2008**, 112, 2648-2648 2.2
- 39 Immunomodulatory Effects of Lenalidomide and Bortezomib on Bone Marrow Stroma Cell and CD4 T Cell Interaction in Multiple Myeloma.. *Blood*, **2008**, 112, 1690-1690 2.2
- 38 Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics. *Blood*, **2008**, 112, 219-219 2.2
- 37 TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. *Blood*, **2008**, 112, 2737-2737 2.2
- 36 Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. *Blood*, **2009**, 114, 1722-1722 2.2
- 35 Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.. *Blood*, **2009**, 114, 950-950 2.2
- 34 A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.. *Blood*, **2009**, 114, 3830-3830 2.2
- 33 PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo.. *Blood*, **2009**, 114, 612-612 2.2
- 32 Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics **2011**, 29-42
- 31 Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone. *Blood*, **2010**, 116, 618-618 2.2
- 30 An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway. *Blood*, **2010**, 116, 2992-2992 2.2

- 29 Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. *Blood*, **2010**, 116, 1838-1838 2.2
- 28 Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. *Blood*, **2010**, 116, 456-456 2.2
- 27 Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function. *Blood*, **2010**, 116, 451-451 2.2
- 26 Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation. *Blood*, **2010**, 116, 4064-4064<sup>2,2</sup>
- 25 Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study. *Blood*, **2010**, 116, 3023-3023 2.2
- 24 Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications. *Blood*, **2010**, 116, 5016-5016 2.2
- 23 Inhibition of c-Myc Expression and Function in Hematologic Malignancies. *Blood*, **2011**, 118, 1409-1409 2.2
- 22 Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. *Blood*, **2011**, 118, 815-815 2.2
- 21 RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2011**, 118, 4134-4134 2.2
- 20 Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. *Blood*, **2011**, 118, 1442-1442 2.2
- 19 Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes. *Blood*, **2011**, 118, 1377-1377 2.2
- 18 A Novel Acanthoic Acid Analog NPI-1342 Blocks IB Kinase and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells. *Blood*, **2011**, 118, 1841-1841 2.2
- 17 Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia. *Blood*, **2011**, 118, 3989-3989 2.2
- 16 Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing. *Blood*, **2011**, 118, 1838-1838 2.2
- 15 Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple Myeloma. *Blood*, **2012**, 120, 3986-3986 2.2
- 14 Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. *Blood*, **2012**, 120, 565-565 2.2
- 13 Novel Agents in Multiple Myeloma **2013**, 215-228
- 12 Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells. *Blood*, **2012**, 120, 1847-1847 2.2



11	Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 1812-1812	2.2
10	Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents. <i>Blood</i> , <b>2012</b> , 120, 3995-3995	2.2
9	Antitumor Activities Of An Oral Selective HSP90 $\alpha$ Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 4429-4429	2.2
8	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). <i>Blood</i> , <b>2013</b> , 122, 1854-1854	2.2
7	Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation - a case series. <i>British Journal of Haematology</i> , <b>2021</b> , 193, e36-e38	4.5
6	The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 213-215	4.5
5	Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply. <i>Lancet, The</i> , <b>2021</b> , 397, 1621-1623	4.0
4	Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8048-8048	2.2
3	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 12082-12082	2.2
2	Current antibody-based therapies for the treatment of multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , <b>2020</b> , 18, 736-748	0.6
1	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.. <i>Therapeutic Advances in Hematology</i> , <b>2022</b> , 13, 20406207221088458	5.7